Developing of a new Pharmacophore Containing Sulfonyl Fluoride Group as Potential Gastrointestinal Lipase Inhibitors

Over the last four dacades, obesity has emerged as a significant globale health issue, closely associated with several serious condition including diabetes and heart diseases. Alarmingly, the prevalence of obesity continues to rise each year, and effective solutions seem elusive. While various strategies and medications have been introduced to tackle obesity and support weight loss; many of these options come with drawbacks, such as the risk of malnutrition and inconsistent results due to limited effectiveness. In this study, we will adopt a molecular modelling approach using pharmacophore based virtual screening and molecular docking studies to design potential oral pancreatic lipase inhibitors which prevent excess fatty acid absorption and promotes weight loss, all while minimizing intestinal absorption to avoid possible systemic side effects.